The FDA approves melphalan flufenamide for patients with relapsed or refractory myelomaAccess, MyelomaMarch 1, 2021
Generating recommendations for patient- reported outcome (PRO): SISAQOL-IMIMPE, Patient evidenceFebruary 18, 2021
Selinexor receives positive opinion from the EMA for the treatment of refractory myelomaAccess, MyelomaJanuary 30, 2021
Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosisAccess, AL amyloidosisJanuary 17, 2021
Watch the webinar on ASH 2020 myeloma and AL amyloidosis highlightsAL amyloidosis, Conferences, MPE, Myeloma, VideosDecember 18, 2020
